EW
ABMD

Evoke Wealth’s Abiomed Inc ABMD Stock Holding History

Evoke Wealth’s Portfolio ABMD Stock Details ABMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-22
Closed -$5K – 1230
2022
Q3 		$5K Buy
22
+12
+120% +$3.24K ﹤0.01% 902
2022
Q2 		$2K Sell
10
-7
-41% -$1.89K ﹤0.01% 1089
2022
Q1 		$6K Buy
+17
New +$5.23K ﹤0.01% 889
2020
Q2 		– Sell
-3
Closed -$435 – 1225
2020
Q1 		$435 Hold
3
– – ﹤0.01% 1033
2019
Q4 		$512 Sell
3
-3
-50% -$556 ﹤0.01% 1190
2019
Q3 		$1.07K Buy
+6
New +$1.3K ﹤0.01% 1303

Other funds holding ABMD

TRSOTSOK
Teachers Retirement System of the State of Kentucky Frankfort, Kentucky $12.9B AUM 31.03% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
AW
Avion Wealth The Woodlands, Texas $484M AUM 15.17% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Evoke Wealth's ABMD Position: Q4 2022 in Review

Evoke Wealth sold out of Abiomed Inc (ABMD) in Q4 2022, closing a stake of 22 shares — an estimated $5K sold.

Evoke Wealth first reported a position in ABMD in Q3 2019 and held it in 6 quarters. The position peaked at $6K in Q1 2022. 8 funds tracked by Wall St. Rank hold ABMD as of Q4 2022.

  • Evoke Wealth reported no remaining Abiomed Inc position as of Q4 2022 after selling out during the quarter.
  • Evoke Wealth sold 22 Abiomed Inc shares in Q4 2022, an estimated $5K.
  • Evoke Wealth first reported a position in Abiomed Inc in Q3 2019 and held it in 6 quarters.
  • Evoke Wealth's Abiomed Inc position peaked at $6K in Q1 2022.
  • 8 funds tracked by Wall St. Rank held Abiomed Inc as of Q4 2022.

Based on Evoke Wealth's 13F filing for Q4 2022, filed 10 Feb 2023.